Gibson Dunn Advises MoonLake Immunotherapeutics on $75 Million Offering of Class A Ordinary Shares

Firm News  |  November 6, 2025

---

Gibson Dunn represented MoonLake Immunotherapeutics in a public offering of Class A ordinary shares generating gross proceeds of approximately $75 million.

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland.

Gibson Dunn regularly advises life sciences companies on capital markets transactions and public offerings in the biopharmaceutical sector.

The Gibson Dunn team included Ryan Murr, Branden Berns, Nick Linke, Lauren Navarro, Mashoka Maimona, and Risa Nakagawa.